WAYNE, Pa. – Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the expansion of its QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin)...
treatment News
Wayne, Pa. — Palvella Therapeutics, Inc., a late clinical-stage biopharmaceutical company whose vision is to become the leading rare disease company focused on developing and commercializing novel therapies to treat individuals suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, announced positive topline results from...
WAYNE, Pa. — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced a new product candidate,...
WAYNE, Pa. — (Nasdaq: PVLA) Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced it has received the second year of funding...
MINNEAPOLIS — Panbela Therapeutics, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces the publication of clinical data from studies of CPP-1X (also known as α-Difluoromethylornithine (DFMO) or Eflornithine) in neuroblastoma. According to Hogarty et al, children with relapsed...
Houston, TX – The use of high-protease pancreatic replacement therapy demonstrated improvement in maladaptive behaviors, such as irritability, in preschool children with autism spectrum disorder (ASD), according to research conducted at 32 clinical sites, including UTHealth Houston. The study was published recently in JAMA Network Open. “Children who have ASD...
PITTSBURGH, PA — PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it was selected by Chiesi Global Rare Diseases, a business unit of the Chiesi Group, for the distribution of Filsuvez® topical gel, the first approved treatment for...
CAMBRIDGE, Mass.— Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced preliminary clinical data demonstrating the therapeutic potential of its lead investigational Helicon™ peptide, FOG-001 – the first and only direct inhibitor of the “undruggable” β-catenin:TCF interaction – in adamantinomatous craniopharyngioma...
CHICAGO – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded by Paragon Biosciences to develop treatments for central nervous system movement disorders and fluency disorders, today announced positive topline results from its Phase 2b clinical study (D1AMOND Study) evaluating the efficacy and safety of ecopipam (EBS-101), an investigational, first-in-class, dopamine-1 (D1) receptor...
CAMBRIDGE, Mass. – Paragonix Technologies, Inc. is announcing the release of the recently developed Paragonix Web Portal, an accessible support platform that connects with the Paragonix App and donor organ preservation devices to provide transplant teams the ability to digitally participate in live sessions or review historical cases and clinical...